Cargando…

Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child

CONTEXT: Inactivating germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene are linked to pituitary adenoma predisposition. Here, we present the youngest known patient with AIP-related pituitary adenoma. CASE DESCRIPTION: The patient presented at the age of 4 years with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dutta, Pinaki, Reddy, Kavita S, Rai, Ashutosh, Madugundu, Anil K, Solanki, Hitendra S, Bhansali, Anil, Radotra, Bishan D, Kumar, Narendra, Collier, David, Iacovazzo, Donato, Gupta, Prakamya, Raja, Remya, Gowda, Harsha, Pandey, Akhilesh, Devgun, Jagtar Singh, Korbonits, Márta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619489/ https://www.ncbi.nlm.nih.gov/pubmed/31125088 http://dx.doi.org/10.1210/jc.2019-00432

Ejemplares similares

Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes
por: Das, Liza, et al.
Publicado: (2021)

Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas
por: Das, Liza, et al.
Publicado: (2021)

Posterior pituitary tumours: patient outcomes and determinants of disease recurrence or persistence
por: Das, Liza, et al.
Publicado: (2021)

Risk category system to identify pituitary adenoma patients with AIP mutations
por: Caimari, Francisca, et al.
Publicado: (2018)

Imatinib Inhibits GH Secretion From Somatotropinomas
por: Gupta, Prakamya, et al.
Publicado: (2018)

Unusual AIP mutation and phenocopy in the family of a young patient with acromegalic gigantism
por: Imran, Syed Ali, et al.
Publicado: (2018)

The outcome of TSHoma from a tertiary care institute in India
por: Dutta, Aditya, et al.
Publicado: (2021)

ODP368 Hyper-phosphorylation of β-catenin at Serine552: predictive marker of invasion and recurrence of Non-Functioning Pituitary Tumours (NFPTs)
por: Rai, Ashutosh, et al.
Publicado: (2022)

Effective Long-term Pediatric Pegvisomant Monotherapy to Final Height in X-linked Acrogigantism
por: Burren, Christine P, et al.
Publicado: (2023)

Pegvisomant in acromegaly: an update
por: Giustina, A., et al.
Publicado: (2017)

AIP variant causing familial prolactinoma
por: Carty, David M., et al.
Publicado: (2020)

Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors
por: Marques, Pedro, et al.
Publicado: (2020)

Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations
por: Hernández-Ramírez, Laura C., et al.
Publicado: (2016)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

Nanomedicines in the treatment of acromegaly: focus on pegvisomant
por: Roelfsema, Ferdinand, et al.
Publicado: (2006)

Pegvisomant for acromegaly: does it always works?
por: Neggers, Sebastian J., et al.
Publicado: (2019)

Choice of fluid therapy in patients of craniopharyngioma in the perioperative period: A hospital-based preliminary study
por: Mukherjee, K. K., et al.
Publicado: (2014)

Unusual presentations of differentiated thyroid cancer: analysis of 55 cases from North India
por: Bhansali, Anil, et al.
Publicado: (2005)

Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Novel AIP mutation in exon 6 causing acromegaly in a German family
por: Detomas, M., et al.
Publicado: (2023)

IL-17 A correlates with disease progression in papillary thyroid carcinoma
por: Banerjee, Sohini, et al.
Publicado: (2023)

Structure of the TPR Domain of AIP: Lack of Client Protein Interaction with the C-Terminal α-7 Helix of the TPR Domain of AIP Is Sufficient for Pituitary Adenoma Predisposition
por: Morgan, Rhodri M. L., et al.
Publicado: (2012)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Brazilian multicenter study on pegvisomant treatment in acromegaly
por: Boguszewski, Cesar L., et al.
Publicado: (2019)

Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

In vivo bioassay to test the pathogenicity of missense human AIP variants
por: Aflorei, Elena Daniela, et al.
Publicado: (2018)

THU079 Danio Rerio (Zebrafish): A New Model Of AIP Loss Of Function
por: Wang, Xian, et al.
Publicado: (2023)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

Phosphorylation of β-catenin at Serine552 correlates with invasion and recurrence of non-functioning pituitary neuroendocrine tumours
por: Rai, Ashutosh, et al.
Publicado: (2022)

Primary hyperparathyroidism in north India: a description of 52 cases
por: Bhansali, Anil, et al.
Publicado: (2005)

SAT-462 AIP Mutation-Positive Patients with Somatotropinomas End up Taller and Requiring Radiotherapy More Often Compared to AIP Mutation-Negative Patients: Data from 784 Familial and Young-Onset Cases
por: Marques, Pedro, et al.
Publicado: (2019)

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
por: Giustina, A., et al.
Publicado: (2014)

Safety and Efficacy of Pegvisomant in Pediatric Growth Hormone Excess
por: Tatsi, Christina, et al.
Publicado: (2021)

Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma
por: Banerjee, Sohini, et al.
Publicado: (2022)

Landscape of Molecular Events in Pituitary Apoplexy
por: Gupta, Prakamya, et al.
Publicado: (2018)

Metformin upregulates mitophagy in patients with T2DM: A randomized placebo‐controlled study
por: Bhansali, Shipra, et al.
Publicado: (2020)

SAT-LB056 Is AIP a Tumor Suppressor or an Oncogene? AIP as a Novel Regulator of the Oncogene BCL6 in Diffuse Large B Cell Lymphoma
por: BARRY, SAYKA, et al.
Publicado: (2019)

Circulating aryl hydrocarbon receptor-interacting protein (AIP) is independent of GH secretion
por: Stojanovic, Marko, et al.
Publicado: (2019)

AIP Annual Meeting
por: Abashian, Alexander
Publicado: (1984)

AIP Annual Meeting
por: Margolis, Bernard, et al.
Publicado: (1980)

Cannot write session to /tmp/vufind_sessions/sess_molp0eroof2npi6kcsa29vqabr